You are here
P&T November 2015
Although the health care marketplace is changing rapidly, some things have not changed, including the need for P&T committees and organizations’ management to beware of ethical and legal issues such as discrimination, quotas, and understaffing.
Parkinson’s motor complications include wearing-off, a delayed or absent response to carbidopa/levodopa therapy, freezing of gait, dyskinesias, and dystonias. Treatment may include medication adjustments, such as increased dopaminergic stimulation.
Up to 70 million U.S. adults have chronic sleep and wakefulness disorders. Therapies may include prescription medications approved by the Food and Drug Administration, off-label treatments, over-the-counter drugs, and herbal therapies.
The European Cancer Congress, which attracts a range of European cancer groups, reflected intense interest in immunotherapies. we review key sessions, including three on the anti-programmed death-1 agent nivolumab, each in a different disease setting.
Future therapies for growth hormone deficiency are expected to include long-acting formulations that may encourage increased use of and adherence to these products.
The index of suspicion: red flags warn of safety threats.
Pharmacies wrestle with the FDA’s new drug-tracing rule.
FDA approvals, drug indications, and updates
Evolocumab (Repatha) for patients with hypercholesterolemia whose condition has not been controlled by statins and other therapies; trifluridine/tipiracil (Lonsurf) for metastatic colorectal cancer; and blood coagulation factor VIII (Nuwiq) for adults and children with hemophilia A
Afrezza (insulin human) inhalation powder: a new inhaled insulin for the management of type-1 or type-2 diabetes mellitus